Your session is about to expire
← Back to Search
Other
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
Phase 1
Waitlist Available
Research Sponsored by Athira Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.
Summary
This trial tests a new drug called ATH-1020 in healthy young and elderly people to see if it is safe and how the body handles it. Researchers will also check if the drug can reach the brain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~samples collected pre-dose on day 1 and predetermined timepoints on day 1, 9, and 10, within 24 hours post-dose.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Secondary study objectives
Amount of IMP excreted unchanged in the urine (Ae)
Area under the plasma concentration time curve (AUC)
Half-life (t1/2)
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ATH-1020Experimental Treatment1 Intervention
ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).
Group II: PlaceboPlacebo Group1 Intervention
Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATH-1020
2022
Completed Phase 1
~40
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Athira PharmaLead Sponsor
7 Previous Clinical Trials
1,262 Total Patients Enrolled
Biotrial Inc.UNKNOWN
1 Previous Clinical Trials
88 Total Patients Enrolled
Alturas Analytics, Inc.UNKNOWN
1 Previous Clinical Trials
8 Total Patients Enrolled